Canaccord noted the NIH is subject to a "march-in" request from six Senators who are requesting a public hearing on drug pricing, including the pricing of Xtandi, which is being developed by Medivation (MDVN) in collaboration with Astellas (ALPMY). The firm said the NIH has rejected all prior march-in requests on drug pricing, so they see minimal likelihood of any changes in U.S. Xtandi prices. In addition, the hearing is more about Medicare copays than the price of drugs in the healthcare system, said Canaccord. The firm maintained its Hold rating and $45 price target on Medivation shares.